Aprea Therapeutics Share Holder Equity 2018-2024 | APRE

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Aprea Therapeutics share holder equity from 2018 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Aprea Therapeutics share holder equity from 2018 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$173B
Vertex Pharmaceuticals (VRTX)	$129.2B
Bristol Myers Squibb (BMY)	$121.3B
Gilead Sciences (GILD)	$120.8B
CSL (CSLLY)	$91.5B
Regeneron Pharmaceuticals (REGN)	$90.7B
GSK (GSK)	$75.3B
Alnylam Pharmaceuticals (ALNY)	$36.1B
Argenex SE (ARGX)	$35.2B
BioNTech SE (BNTX)	$26.1B
Biogen (BIIB)	$25.1B
Illumina (ILMN)	$24B
BeiGene (BGNE)	$20B
Moderna (MRNA)	$16.5B
Incyte (INCY)	$15.7B
Genmab (GMAB)	$15.4B
Vaxcyte (PCVX)	$12.9B
Insmed (INSM)	$12.8B
BioMarin Pharmaceutical (BMRN)	$12.6B
Bio-Techne Corp (TECH)	$11.9B
Sarepta Therapeutics (SRPT)	$11.3B
Exelixis (EXEL)	$10.3B
Revolution Medicines (RVMD)	$10.2B
QIAGEN (QGEN)	$10.1B
Intra-Cellular Therapies (ITCI)	$9.7B
Exact Sciences (EXAS)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$8.7B
Repligen (RGEN)	$7.8B
Ascendis Pharma (ASND)	$7.8B